Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.

Actin interaction and regulation of cyclin-dependent kinase 5/p35 complex activity.

Xu J, Tsutsumi K, Tokuraku K, Estes KA, Hisanaga S, Ikezu T.

J Neurochem. 2011 Jan;116(2):192-204. doi: 10.1111/j.1471-4159.2010.06824.x.

2.

CDK5 activator protein p25 preferentially binds and activates GSK3β.

Chow HM, Guo D, Zhou JC, Zhang GY, Li HF, Herrup K, Zhang J.

Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):E4887-95. doi: 10.1073/pnas.1402627111. Epub 2014 Oct 20. Erratum in: Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):E3313.

3.

The neuronal p35 activator of Cdk5 is a novel F-actin binding and bundling protein.

He L, Zhang Z, Yu Y, Ahmed S, Cheung NS, Qi RZ.

Cell Mol Life Sci. 2011 May;68(9):1633-43. doi: 10.1007/s00018-010-0562-9. Epub 2010 Oct 26.

PMID:
20976519
4.

Two Degradation Pathways of the p35 Cdk5 (Cyclin-dependent Kinase) Activation Subunit, Dependent and Independent of Ubiquitination.

Takasugi T, Minegishi S, Asada A, Saito T, Kawahara H, Hisanaga S.

J Biol Chem. 2016 Feb 26;291(9):4649-57. doi: 10.1074/jbc.M115.692871. Epub 2015 Dec 2.

5.

Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia.

Seo J, Kritskiy O, Watson LA, Barker SJ, Dey D, Raja WK, Lin YT, Ko T, Cho S, Penney J, Silva MC, Sheridan SD, Lucente D, Gusella JF, Dickerson BC, Haggarty SJ, Tsai LH.

J Neurosci. 2017 Oct 11;37(41):9917-9924. doi: 10.1523/JNEUROSCI.0621-17.2017. Epub 2017 Sep 14.

6.

Phosphorylation of drebrin by cyclin-dependent kinase 5 and its role in neuronal migration.

Tanabe K, Yamazaki H, Inaguma Y, Asada A, Kimura T, Takahashi J, Taoka M, Ohshima T, Furuichi T, Isobe T, Nagata K, Shirao T, Hisanaga S.

PLoS One. 2014 Mar 17;9(3):e92291. doi: 10.1371/journal.pone.0092291. eCollection 2014.

7.

The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35.

Amin ND, Zheng Y, Bk B, Shukla V, Skuntz S, Grant P, Steiner J, Bhaskar M, Pant HC.

Mol Biol Cell. 2016 Nov 1;27(21):3221-3232. Epub 2016 Sep 14.

8.

p39 Is Responsible for Increasing Cdk5 Activity during Postnatal Neuron Differentiation and Governs Neuronal Network Formation and Epileptic Responses.

Li W, Allen ME, Rui Y, Ku L, Liu G, Bankston AN, Zheng JQ, Feng Y.

J Neurosci. 2016 Nov 2;36(44):11283-11294.

9.

A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation.

Zheng YL, Amin ND, Hu YF, Rudrabhatla P, Shukla V, Kanungo J, Kesavapany S, Grant P, Albers W, Pant HC.

J Biol Chem. 2010 Oct 29;285(44):34202-12. doi: 10.1074/jbc.M110.134643. Epub 2010 Aug 18.

10.

Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.

Sun LH, Ban T, Liu CD, Chen QX, Wang X, Yan ML, Hu XL, Su XL, Bao YN, Sun LL, Zhao LJ, Pei SC, Jiang XM, Zong DK, Ai J.

J Neurochem. 2015 Sep;134(6):1139-51. doi: 10.1111/jnc.13212.

11.

Involvement of aberrant cyclin-dependent kinase 5/p25 activity in experimental traumatic brain injury.

Yousuf MA, Tan C, Torres-Altoro MI, Lu FM, Plautz E, Zhang S, Takahashi M, Hernandez A, Kernie SG, Plattner F, Bibb JA.

J Neurochem. 2016 Jul;138(2):317-27. doi: 10.1111/jnc.13620. Epub 2016 May 25.

12.

Cyclin I and p35 determine the subcellular distribution of Cdk5.

Hagmann H, Taniguchi Y, Pippin JW, Kauerz HM, Benzing T, Shankland SJ, Brinkkoetter PT.

Am J Physiol Cell Physiol. 2015 Feb 15;308(4):C339-47. doi: 10.1152/ajpcell.00168.2014. Epub 2014 Dec 10.

13.

p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease.

Hallows JL, Iosif RE, Biasell RD, Vincent I.

J Neurosci. 2006 Mar 8;26(10):2738-44.

14.

Quantitative measurement of in vivo phosphorylation states of Cdk5 activator p35 by Phos-tag SDS-PAGE.

Hosokawa T, Saito T, Asada A, Fukunaga K, Hisanaga S.

Mol Cell Proteomics. 2010 Jun;9(6):1133-43. doi: 10.1074/mcp.M900578-MCP200. Epub 2010 Jan 23.

15.

Resveratrol inhibits Cdk5 activity through regulation of p35 expression.

Utreras E, Terse A, Keller J, Iadarola MJ, Kulkarni AB.

Mol Pain. 2011 Jul 7;7:49. doi: 10.1186/1744-8069-7-49.

16.

The inhibition of Cdk5 activity after hypoxia/ischemia injury reduces infarct size and promotes functional recovery in neonatal rats.

Tan X, Chen Y, Li J, Li X, Miao Z, Xin N, Zhu J, Ge W, Feng Y, Xu X.

Neuroscience. 2015 Apr 2;290:552-60. doi: 10.1016/j.neuroscience.2015.01.054. Epub 2015 Feb 7.

PMID:
25665755
17.

The levels of cdk5 and p35 proteins and tau phosphorylation are reduced during neuronal apoptosis.

Kerokoski P, Suuronen T, Salminen A, Soininen H, Pirttilä T.

Biochem Biophys Res Commun. 2001 Feb 2;280(4):998-1002.

PMID:
11162625
18.

Structural basis for the different stability and activity between the Cdk5 complexes with p35 and p39 activators.

Saito T, Yano M, Kawai Y, Asada A, Wada M, Doi H, Hisanaga S.

J Biol Chem. 2013 Nov 8;288(45):32433-9. doi: 10.1074/jbc.M113.512293. Epub 2013 Sep 30.

19.

The Cdk5/p35 kinases modulate leptin-induced STAT3 signaling.

He Y, Kastin AJ, Hsuchou H, Pan W.

J Mol Neurosci. 2009 Sep;39(1-2):49-58. doi: 10.1007/s12031-008-9174-3. Epub 2009 Jan 21.

20.

Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.

Kesavapany S, Zheng YL, Amin N, Pant HC.

Biotechnol J. 2007 Aug;2(8):978-87. Review.

PMID:
17526058

Supplemental Content

Support Center